Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the summit.
Friday, March 4, 2022 |
|
8:00am | Horizon CME App Overview |
8:10am | Welcome, Introductions, & CE Housekeeping |
8:15am |
(01) The Evolution of Drug Therapy in Oncology: Recent Advances in Cancer Drug Therapy » Valerie Relias, PharmD - Tufts Medical Center |
9:15am | Break and Exhibitor Announcement |
9:35am | (02A) Small Cell Lung Cancer: Recent Advances in Therapy » Catherine B. Meador, MD. PhD - Dana-Farber Cancer Institute (02B) CAR T-Cell Therapy: Current Status in Oncology » Caron Jacobson, MD, MMSc Physician - Dana-Farber Cancer Institute |
10:35am | Break & Virtual Exhibit Hall | Meet-the-Clinician |
10:55am |
(03A) Financial Toxicities and Health Equity Access |
11:55am | Break & Virtual Exhibit Hall | Meet-the-Clinician |
12:10pm |
Non-CME/CE Presentation Sponsored by Pfizer Oncology - Topic: Clinical Trial Evidence for a CDK4/6 Inhibitor Combination Therapy Complemented by an Evaluation of Real-World Effectiveness | Speaker: Christine Helou, MSN, FNP-BC, OCN |
12:55pm |
(04) Integrating Palliative Care in the Daily Oncology Practice |
1:55pm |
(05A) Triple-Negative Metastatic Breast Cancer: Expanding Treatment Beyond Chemotherapy » V. K. Gadi, MD, PhD - Professor of Medicine and Director of Medical Oncology, University of Illinois at Chicago (05B) New Strategies in Chronic Lymphocytic Leukemia » Charlene Kabel, PharmD, BCOP - Memorial Sloan Kettering Cancer Center |
2:55pm | (06) Cancer-Related Thrombosis: The Great Debate on the Best Way to Anticoagulate » Allison Schepers, PharmD, BCOP - University of Michigan College of Pharmacy » Danielle Otto, PharmD, BCOP - University of Kentucky Healthcare |
4:10pm | Closing Comments |
Saturday, March 5, 2022 |
||
7:10am | Non-CME/CE Morning Symposium sponsored by Janssen Oncology: Update on the Treatment of Patients with Multiple Myeloma » Perry Cook MD; |
|
8:00am | Virtual Platform Overview | |
8:10am | Welcome, Introductions, & CE Housekeeping | |
8:15am |
(07A) Targeting Advanced Renal Cell Carcinoma (07B) Benign Hematology 101: Iron Deficiency Anemia |
|
9:15am | Break and Exhibitor Announcements | |
9:35am |
|
|
10:35am | Break & Virtual Exhibit Hall | Meet-the-Clinician | |
10:55am |
(09) Compassion Fatigue & Provider Burnout: How Can Self-Care Strategies Enhance Provider Well-Being? |
|
11:55am | Break & Virtual Exhibit Hall | Meet-the-Clinician | |
12:10pm | Non-CME/CE Presentation Sponsored by Incyte: : PEMAZYRE® (pemigatinib): The First FDA-Approved Treatment for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma (CCA) with an FGFR2 Fusion or Rearrangement » Gabriel Schwartz, MSN, FNP-BC, AOCNP |
|
12:55pm | (10) Symptom Management in Oncology: Helping Patients Improve Their Quality of Life » Kathy Chuang, MD MGH » Michael L. Dougan, MD, PhD |
|
1:55pm |
(11A) Esophageal and Gastroesophageal Junction Cancers: Strategies in Treatment and Management (11B) Managing Diffuse Large B-cell Lymphoma in 2022: Novel Therapeutic Strategies in the Relapsed/Refractory Setting |
|
2:55pm | Closing Comments |
$80.00